Literature DB >> 30084163

Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection.

Özgür Akgül1, Fabio Bagante1,2, Griffin Olsen1, Jordan M Cloyd1, Matthew Weiss3, Katiuscha Merath1, Sorin Alexandrescu4, Hugo P Marques5, Luca Aldrighetti6, Shishir K Maithel7, Carlo Pulitano8, Todd W Bauer9, Feng Shen10, George A Poultsides11, Olivier Soubrane12, Guillaume Martel13, B Groot Koerkamp14, Alfredo Guglielmi2, Endo Itaru15, Timothy M Pawlik1.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy. We sought to examine the association between preoperative prognostic nutritional index (PNI) and long-term overall survival among patients with ICC who underwent curative-intent resection.
METHODS: Patients who underwent hepatectomy for ICC between 1990 and 2015 were identified using an international multi-institutional database. Clinic-pathological characteristics and long-term outcomes of patients with PNI ≥ 40 and <40 were compared using univariable and multivariable analyses.
RESULTS: Among 637 patients, 53 patients had PNI < 40 (8.3%) and 584 patients had PNI ≥ 40 (91.7%). While there was no difference between PNI groups with regard to tumor size (P = .87), patients with PNI < 40 were more likely to have multifocal disease (PNI < 40, n = 16, 30.2% vs PNI ≥ 40, n = 65, 11.1%; P < 0.001), poorly differentiated or undifferentiated ICC (PNI < 40, n = 13, 25.5% vs PNI ≥ 40, n = 75, 13.1%; P = 0.020) and T2/T3/T4 disease vs patients with PNI ≥ 40 (PNI < 40, n = 38, 71.7% vs PNI ≥ 40, n = 265, 45.4%; P < 0.001). Patients with PNI ≥ 40 had better OS vs patients with PNI < 40 (5-year OS: PNI ≥ 40: 47.5%, 95% CI, 42.2 to 52.6% vs PNI < 40: 24.6%, 95% CI, 12.1 to 39.6%; P < 0.001). On multivariable analysis, PNI < 40 remained associated with increase risk of death (HR, 1.71; 95% CI, 1.15 to 2.53; P = 0.008).
CONCLUSION: A low preoperative PNI was associated with a more aggressive ICC phenotype. After controlling for these factors, PNI remained independently associated with a markedly worse prognosis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; lymphocytes; nutritional index; surgery

Mesh:

Year:  2018        PMID: 30084163     DOI: 10.1002/jso.25140

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  15 in total

1.  Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.

Authors:  Ali Ogul; Mehmet Mutlu Kidi; Mahmut Buyuksimsek
Journal:  J Gastrointest Cancer       Date:  2021-03

2.  Safety and benefits of major hepatectomy with extrahepatic bile duct resection in older perihilar cholangiocarcinoma patients.

Authors:  Koki Maeda; Naohisa Kuriyama; Takahiro Ito; Kazuyuki Gyoten; Aoi Hayasaki; Takehiro Fujii; Yusuke Iizawa; Yasuhiro Murata; Akihiro Tanemura; Masashi Kishiwada; Shugo Mizuno
Journal:  Langenbecks Arch Surg       Date:  2022-08-23       Impact factor: 2.895

Review 3.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

4.  The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Amika Moro; Rittal Mehta; Kota Sahara; Diamantis I Tsilimigras; Anghela Z Paredes; Ayesha Farooq; J Madison Hyer; Itaru Endo; Feng Shen; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Olivier Soubrane; Bas G Koerkamp; Kazunari Sasaki; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-03-20       Impact factor: 5.344

5.  Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.

Authors:  Kyohei Yugawa; Shinji Itoh; Tomoharu Yoshizumi; Akinari Morinaga; Norifumi Iseda; Takeo Toshima; Noboru Harada; Kenichi Kohashi; Yoshinao Oda; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2021-06-12       Impact factor: 3.402

6.  The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen.

Authors:  Mahmut Buyuksimsek; Mehmet Mutlu Kidi; Ali Ogul; Cem Mirili; Semra Paydas
Journal:  J Gastrointest Cancer       Date:  2021-03

7.  Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8+ tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma.

Authors:  Katsuki Miyazaki; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Yu Saito; Shinichiro Yamada; Kazunori Tokuda; Shohei Okikawa; Shoko Yamashita; Takeshi Oya; Koichi Tsuneyama; Mitsuo Shimada
Journal:  Surg Today       Date:  2021-05-19       Impact factor: 2.549

8.  The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers.

Authors:  Daisuke Noguchi; Naohisa Kuriyama; Yuki Nakagawa; Koki Maeda; Toru Shinkai; Kazuyuki Gyoten; Aoi Hayasaki; Takehiro Fujii; Yusuke Iizawa; Akihiro Tanemura; Yasuhiro Murata; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno
Journal:  PLoS One       Date:  2021-01-28       Impact factor: 3.240

9.  Effect of Tumor Size on Long-Term Survival After Resection for Solitary Intrahepatic Cholangiocarcinoma.

Authors:  Junjie Kong; Yukun Cao; Jiawei Chai; Xihan Liu; Cunhu Lin; Jianping Wang; Jun Liu
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

10.  Prognostic Nutritional Index is a Predictor of Free Flap Failure in Extremity Reconstruction.

Authors:  Jihion Yu; Joon Pio Hong; Hyunsuk Peter Suh; Jun-Young Park; Doo-Hwan Kim; Seungsoo Ha; Joonho Lee; Jai-Hyun Hwang; Young-Kug Kim
Journal:  Nutrients       Date:  2020-02-21       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.